The use of 3'-deoxy-3'-18F-fluorothymidine (FLT) PET in the assessment of long-term survival in breast cancer patients treated with neoadjuvant chemotherapy.
Benjamin E UeberrothJawana M Lawhorn-CrewsLance K HeilbrunDaryn W SmithJanice AkouryRouba Ali-FehmiNicole T EiselerAnthony F ShieldsPublished in: Annals of nuclear medicine (2019)
Further study of a larger sample size is needed to examine the potential role for FLT-PET in predicting response to neoadjuvant treatment, particularly in correlating with long-term overall and progression-free survival. Our study is limited by small sample size, but does suggest that FLT-PET has a role in the long-term prognosis of breast cancer treated with NAC and surgical resection which is worthy of further study.